MYB binding protein 1aGenealiases: P160 · PAP2 · Pol5
Q-omics provides the consensus-scored MYBBP1A profile across patient tissues and cancer cell-line models. MYBBP1A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYBBP1A is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, MYBBP1A protein abundance shows 30,898 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where MYBBP1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYBBP1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYBBP1A survival associations across molecular data types. MYBBP1A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYBBP1A RNA expression–survival associations across cancer types. High MYBBP1A expression shows unfavorable associations in ACC, KIRP, KICH, LGG and THCA, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYBBP1A RNA expression.
This table summarizes MYBBP1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYBBP1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYBBP1A shows higher tumor expression in COAD, KIRP, KIRC, STAD, HNSC and BLCA. The COAD box plot shows higher MYBBP1A RNA expression in tumor versus normal tissue (log2 FC = +1.425, t-test p < 0.001).
This table shows molecular features associated with MYBBP1A in patient tissues and cancer cell lines. In patient samples, MYBBP1A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYBBP1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
